GlassScriptPhysician profile
Victor L Carlo
NPI 1104968676
$3,241.69
in general payments reported to CMS, 2019-2025
17 companies · $906 in 2025
The $906 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $124 · 2021: $287 · 2022: $607 · 2023: $278 · 2024: $386 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,705.44 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Pharmaceuticals, INC | $432.78 | 2020-2025 | Stelara, Tremfya |
| Ferring Pharmaceuticals INC. | $177.43 | 2022 | |
| Olympus Latin America, INC. | $146.86 | 2025 | Evis Exera II Ultrasound Gastrovideoscope |
| Takeda Pharmaceuticals U.S.A., INC. | $119.94 | 2025 | Entyvio |
| Medtronic, INC. | $110.45 | 2019 | |
| Janssen Biotech, INC. | $99.00 | 2020 | |
| Boston Scientific Corporation | $98.79 | 2019 | |
| Merck Sharp & Dohme LLC | $98.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.12 | 2023-2024 | Cyltezo |
| Amgen INC. | $40.00 | 2023 | Amjevita |
| Organon LLC | $33.33 | 2025 | |
| Madrigal Pharmaceuticals | $25.00 | 2025 | Rezdiffra |
| Genzyme Corporation | $25.00 | 2022 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $23.45 | 2025 | Omvoh |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.30 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Carlo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.